Atıf İçin Kopyala
Cure M. C., Cure E., Kalkan Y., Tumkaya L., Aydin I., Kirbas A., ...Daha Fazla
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, cilt.25, sa.2, ss.219-226, 2016 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
25
Sayı:
2
-
Basım Tarihi:
2016
-
Doi Numarası:
10.17219/acem/33250
-
Dergi Adı:
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.219-226
-
Anahtar Kelimeler:
ischemia, reperfusion injury, adalimumab, carbonic anhydrases, tumor necrosis factor alpha, CARBONIC-ANHYDRASE-II, ISCHEMIA-REPERFUSION, ISCHEMIA/REPERFUSION INJURY, RADICAL-ANION, BICARBONATE, INFLAMMATION, EXPRESSION, INTERLEUKIN-6, PRETREATMENT, INHIBITION
-
Recep Tayyip Erdoğan Üniversitesi Adresli:
Evet
Özet
Background. Adalimumab (ADA) is a potent inhibitor of tumor necrosis factor (TNF-alpha). ADA treatment suppresses proinflammatory cytokines, leading to a decrease or inhibition of the inflammatory process.